Katherine Wu

Katherine Wu

Auto-generated profile, based on publicly available information

Katherine Wu

Department of Pathology, New York University Grossman School of Medicine, New York, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2024 in Nature Cancer
Verified
Journal Article
Closed access
KWKatherine Wu
Katherine Wu
Ahmed Ezat El ZowalatyAhmed Ezat El Zowalaty
Ahmed Ezat El Zowalaty
VSVolkan Sayin
Volkan Sayin
TPThales Papagiannakopoulos
Thales Papagiannakopoulos

5 November 2025 in Nature
Verified
Journal Article
Open access
PDF file
KWKatherine Wu
Katherine Wu
AVAlec J. Vaughan
Alec J. Vaughan
JBJozef P. Bossowski
Jozef P. Bossowski
YHYuan Hao
Yuan Hao
AZAikaterini Ziogou
Aikaterini Ziogou
TPThales Papagiannakopoulos
Thales Papagiannakopoulos
Emerging evidence indicates that cancer cells are susceptible to ferroptosis, a form of cell death that is triggered by uncontrolled lipid peroxidation1,2,3. Despite broad enthusiasm about harnessing ferroptosis as a novel anti-cancer strategy, whether ferroptosis is a barrier to tumorigenesis and can be leveraged therapeutically remains unknown4,5. Here, using genetically engineered mouse models of lung adenocarcinoma, we performed tumour-specific loss-of-function studies of two key ferroptosis suppressors, GPX46,7 and ferroptosis suppressor protein 1 (FSP1)8,9, and observed increased lipid peroxidation and robust suppression of tumorigenesis, suggesting that lung tumours are highly sensitive to ferroptosis. Furthermore, across multiple pre-clinical models, we found that FSP1 was required for ferroptosis protection in vivo, but not in vitro, underscoring a heightened need to buffer lipid peroxidation under physiological conditions. Lipidomic analyses revealed that Fsp1-knockout tumours had an accumulation of lipid peroxides, and inhibition of ferroptosis with genetic, dietary or pharmacological approaches effectively restored the growth of Fsp1-knockout tumours in vivo. Unlike GPX4, expression of FSP1 (also known as AIFM2) was prognostic for disease progression and poorer survival in patients with lung adenocarcinoma, highlighting its potential as a viable therapeutic target. To this end, we demonstrated that pharmacologic inhibition of FSP1 had significant therapeutic benefit in pre-clinical lung cancer models. Our studies highlight the importance of ferroptosis suppression in vivo and pave the way for FSP1 inhibition as a therapeutic strategy for patients with lung cancer.

11 August 2022 in Cancer Research
Verified
Journal Article
Closed access
PDF file
KPKenneth L. Pitter
Kenneth L. Pitter
OGOlivera Grbovic-Huezo
Olivera Grbovic-Huezo
SJSimon Joost
Simon Joost
ASAnupriya Singhal
Anupriya Singhal
MBMelissa Blum
Melissa Blum
TTTuomas Tammela
Tuomas Tammela
Intratumoral heterogeneity and cellular plasticity have emerged as hallmarks of cancer, including pancreatic ductal adenocarcinoma (PDAC). As PDAC portends a dire prognosis, a better understanding of the mechanisms underpinning cellular diversity in PDAC is crucial. Here, we investigated the cellular heterogeneity of PDAC cancer cells across a range of in vitro and in vivo growth conditions using single-cell genomics. Heterogeneity contracted significantly in two-dimensional and three-dimensional cell culture models but was restored upon orthotopic transplantation. Orthotopic transplants reproducibly acquired cell states identified in autochthonous PDAC tumors, including a basal state exhibiting coexpression and coaccessibility of epithelial and mesenchymal genes. Lineage tracing combined with single-cell transcriptomics revealed that basal cells display high plasticity in situ. This work defines the impact of cellular growth conditions on phenotypic diversity and uncovers a highly plastic cell state with the capacity to facilitate state transitions and promote intratumoral heterogeneity in PDAC. Significance: This work provides important insights into how different model systems of pancreatic ductal adenocarcinoma mold the phenotypic space of cancer cells, highlighting the power of in vivo models.

18 February 2026 in Nature
Verified
Journal Article
Open access
PDF file
JBJozef P. Bossowski
Jozef P. Bossowski
RPRay Pillai
Ray Pillai
JKJohn Kilian
John Kilian
ALAngela Wong Lau
Angela Wong Lau
MNMari Nakamura
Mari Nakamura
TPThales Papagiannakopoulos
Thales Papagiannakopoulos
Cancer cells activate the integrated stress response (ISR) to adapt to stress and resist therapy1. ISR signals converge on activating transcription factor 4 (ATF4), which controls cell-intrinsic transcriptional programs that are involved in metabolic adaptation, survival and growth2,3. However, whether the ISR–ATF4 axis influences anti-tumour immune responses remains mostly unknown. Here we show that loss of ATF4 decreases tumour progression considerably in immunocompetent mice, but not in immunocompromised ones, by enhancing T cell-dependent anti-cancer immune responses. An unbiased genetic screen of ATF4-regulated genes identifies lipocalin 2 (LCN2) as the principal ATF4-dependent effector that impairs anti-tumour immunity by favouring infiltration with immunosuppressive interstitial macrophages. Furthermore, we find that LCN2 promotes T cell exclusion and immune evasion in preclinical mouse models, and correlates with decreased T cell infiltration in patients with lung and pancreatic adenocarcinomas. Anti-LCN2 antibodies promote robust anti-tumour T cell responses in mouse models of aggressive solid tumours. Our study shows that the ATF4–LCN2 axis has a cell-extrinsic role in suppressing anti-cancer immunity, and could pave the way for an immunotherapy approach that targets LCN2.

11 August 2025 in bioRxiv
Verified
Preprint
Open access
KWKatherine Wu
Katherine Wu
AVAlec J Vaughan
Alec J Vaughan
JBJozef P Bossowski
Jozef P Bossowski
YHYuan Hao
Yuan Hao
AZAikaterini Ziogou
Aikaterini Ziogou
TPThales Papagiannakopoulos
Thales Papagiannakopoulos
Pre-clinical and clinical studies have demonstrated how dietary antioxidants or mutations activating antioxidant metabolism promote cancer, highlighting a central role oxidative stress in tumorigenesis. However, it is unclear if oxidative stress ultimately increases to a point of cell death. Emerging evidence indicates that cancer cells are susceptible to ferroptosis, a form of cell death triggered by uncontrolled lipid peroxidation 1–3 . Despite broad enthusiasm about harnessing ferroptosis as a novel anti-cancer strategy, whether ferroptosis is a barrier to tumorigenesis and if it can be leveraged therapeutically remains unknown 4,5 . Using genetically-engineered mouse models (GEMMs) of lung adenocarcinoma (LUAD), we performed tumor specific loss-of-function studies of the two key ferroptosis suppressors, glutathione peroxidase 4 ( Gpx4 ) 6,7 and ferroptosis suppressor protein 1 ( Fsp1 ) 8,9 , and observed increased lipid peroxidation and robust suppression of tumorigenesis, suggesting that lung tumors are highly sensitive to ferroptosis. Furthermore, across multiple pre-clinical models, we found that FSP1 was required for ferroptosis protection in vivo , but not in vitro , underscoring a heightened need to buffer lipid peroxidation under physiological conditions. Lipidomic analyses revealed that Fsp1-knockout (Fsp1 KO ) tumors had an accumulation of lipid peroxides, and inhibition of ferroptosis with genetic, dietary, or pharmacological approaches effectively restored the growth of Fsp1 KO tumors in vivo . Unlike GPX4 , FSP1 expression was prognostic for disease progression and poorer survival in LUAD patients, highlighting its potential as a viable therapeutic target. To this end, we demonstrated that pharmacologic inhibition of FSP1 had significant therapeutic benefit in pre-clinical lung cancer models. Our studies highlight the importance of ferroptosis suppression in vivo and pave the way for FSP1 inhibition as a therapeutic strategy in lung cancer patients.

31 March 2023
Verified
Other
Open access
KPKenneth L. Pitter
Kenneth L. Pitter
OGOlivera Grbovic-Huezo
Olivera Grbovic-Huezo
SJSimon Joost
Simon Joost
ASAnupriya Singhal
Anupriya Singhal
MBMelissa Blum
Melissa Blum
TTTuomas Tammela
Tuomas Tammela
Supplementary Figure from Systematic Comparison of Pancreatic Ductal Adenocarcinoma Models Identifies a Conserved Highly Plastic Basal Cell State